UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 1, 2009

Protalix BioTherapeutics, Inc.

(Exact name of registrant as specified in its charter)

Florida		000-27836		65-0643773
(State or other		(Commission		(IRS Employer
jurisdiction of		File Number)		Identification No.)
incorporation)

(Address of principal executive offices) (Zip Code)

 

(Former Name or Former Address, if Changed Since Last Report)

Registrant’s telephone number, including area code: +972-4-988-9488

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 7.01. Regulation FD Disclosure

On June 1, 2009, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing that Dr. David Aviezer, the Company’s President and Chief Executive Officer, will be presenting on June 10, 2009, at the 8th Annual Needham Life Sciences Conference in New York and on June 15, 2009, at the 8^th National Life Science and Technology Week ISLI-Biomed Israel 2009. The Company also announced that Dr. Einat Brill Almon, the Company’s Senior Vice President of Product Development, will be presenting on June 16, 2009, at the 3rd International Conference on Plant-Based Vaccines & Antibodies in Italy.

An audio webcast of Dr. Aviezer’s presentation at the 8th Annual Needham Life Sciences Conference in New York will be available on the Company’s website at www.protalix.com under the events calendar section.

Item 9.01. Financial Statements and Exhibits

(d)		Exhibits
99.1		Press release dated June 1, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Exhibit 99.1

Protalix BioTherapeutics to Present at Three Upcoming Healthcare Conferences

CARMIEL, Israel, June 1, 2009 (Business Wire) — Protalix BioTherapeutics, Inc. (NYSE-AMEX: PLX), today announced that Dr. David Aviezer, the Company’s President and Chief Executive Officer, will be presenting at 8th Annual Needham Life Sciences Conference in New York and the 8^th National Life Science and Technology Week ISLI-Biomed Israel 2009. Additionally, Dr. Einat Brill Almon, the Company’s Senior Vice President of Product Development, will be presenting at the 3rd International Conference on Plant-Based Vaccines & Antibodies in Italy.

The conference schedule is as follows:

8th Annual Needham Life Sciences Conference: Healthcare Today & Tomorrow
Corporate Presentation, June 10 at 2:30 PM ET
New York Palace Hotel, New York, NY
A webcast of this presentation will be available at www.protalix.com

3rd International Conference on Plant-Based Vaccines & Antibodies
Presentation entitled, “‘Novel enzyme replacement therapy for Gaucher disease: Ongoing
Phase III trials with recombinant human glucocerebrosidase expressed in plant cells,”
June 15 at 2:00 PM CET
University of Verona, Verona, Italy

8^th National Life Science and Technology Week ISLI-Biomed Israel 2009
Corporate Presentation, June 16 at the BioPharma Session, 4:20-6:20 PM IDT
David Intercontinental Hotel, Tel-Aviv, Israel

About Protalix BioTherapeutics

Protalix is a biopharmaceutical company. Its goal is to become a fully integrated biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins to be expressed through its proprietary plant cell based expression system. Protalix’s ProCellEx(TM) presents a proprietary method for the expression of recombinant proteins that Protalix believes will allow for the cost-effective, industrial-scale production of recombinant therapeutic proteins. Protalix is conducting a phase III pivotal study for its lead product candidate, prGCD, to be used in enzyme replacement therapy for Gaucher disease, a lysosomal storage disorder in humans. Protalix has reached an agreement with the United States Food and Drug Administration on the final design of the pivotal phase III clinical trial through the FDA’s Special Protocol Assessment (SPA) process. Protalix has completed enrollment for this study and is treating patients in its pivotal phase III clinical trial in North America, South America, Israel, Europe and South Africa. The study is monitored by an independent Data Monitoring Committee including experts in the field, who monitor the on going safety data, which has recently held their last scheduled meeting before the end of the trial. No serious adverse events have been reported in the study. Protalix is also advancing additional recombinant biopharmaceutical drug development programs.

Contact:
Marcy Nanus
The Trout Group, LLC
Telephone: 646-378-2927
Email: mnanus@troutgroup.com